Letter to the Editor

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 9
Volume 18
Issue 9

In response to the article “Oncology takes blame for rising healthcare cost” (page 1, July 2009), I would like to direct Oncology News International readers to two articles on the “Win-Win” initiative. The full text articles are available online for free at:

In response to the article “Oncology takes blame for rising healthcare cost” (page 1, July 2009), I would like to direct Oncology News International readers to two articles on the “Win-Win” initiative. The full text articles are available online for free at:

“Breast Cancer Systemic Therapy: The need for more economically sustainable scientific strategies in the world,” Breast Care 3:434–438, 2008, www.karger.com/brc

“The ‘Win-Win’ initiative: A global, scientifically based approach to resource-sparing treatment for systemic breast cancer therapy,” World J Surg Oncol 7:44, 2009, www.wjso.com/content/7/1/44.

-Prof. Ahmed Elzawawy president, International Campaign for Establishment and Development of Oncology Centres, and director, South and East Mediterranean College of Oncology, Port Said, Egypt

Related Videos
A panel of 3 experts on multiple myeloma
A panel of 3 experts on multiple myeloma
Aparna Parikh, MD, with the Oncology Brothers presenting slides
Aparna Parikh, MD, with the Oncology Brothers presenting slides
Aparna Parikh, MD, with the Oncology Brothers presenting slides
Aparna Parikh, MD, with the Oncology Brothers presenting slides
Aparna Parikh, MD, with the Oncology Brothers presenting slides
Tailoring neoadjuvant therapy regimens for patients with mismatch repair deficient gastroesophageal cancer represents a future step in terms of research.
Not much is currently known about the factors that may predict pathologic responses to neoadjuvant immunotherapy in this population, says Adrienne Bruce Shannon, MD.
The toxicity profile of tislelizumab also appears to look better compared with chemotherapy in metastatic esophageal squamous cell carcinoma.